15 July 2022 | News
SK Biopharmaceuticals, Eurofarma partner for Cenobamate in Latin America
Image credit: shutterstock
South Korea's SK Biopharmaceuticals has entered into a licensing agreement for Eurofarma, a Brazilian pharmaceutical company with business in over 20 countries, to develop and commercialize cenobamate in Latin Americafor the treatment of epilepsy. Cenobamate is approved and available in the United States and Europe for the treatment of partial-onset seizures in adults.
Under the terms of the agreement, SK Biopharmaceuticals has granted Eurofarma the exclusive rights to develop and commercialize cenobamate in Latin America. In return, SK Biopharmaceuticals will receive an upfront payment of $15 million and will be eligible to receive future milestones of up to $47 million, in addition to royalties on sales generated in Latin America.
The agreement reinforces the company's commitment and capabilities in developing medicines for central nervous system disorders and providing treatment options for the epilepsy communities in this region and around the world. Cenobamate has been previously launched in the United States and Europe, and SK Biopharmaceuticals completed partnerships for cenobamate in Japan, China, Canada, and Israel. With this agreement, SK Biopharmaceuticals will now be present in four continents: North America, Europe, Asiaand Latin America.